BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 14715835)

  • 1. Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty.
    Weise M; Flor A; Barnes KM; Cutler GB; Baron J
    J Clin Endocrinol Metab; 2004 Jan; 89(1):103-7. PubMed ID: 14715835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height.
    Lazar L; Kauli R; Pertzelan A; Phillip M
    J Clin Endocrinol Metab; 2002 May; 87(5):2090-4. PubMed ID: 11994346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.
    Antoniazzi F; Bertoldo F; Lauriola S; Sirpresi S; Gasperi E; Zamboni G; Tatò L
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1992-6. PubMed ID: 10372699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
    Pucarelli I; Segni M; Ortore M; Moretti A; Iannaccone R; Pasquino AM
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment with gonadotropin-releasing hormone analog and growth hormone in central precocious puberty.
    Pasquino AM; Municchi G; Pucarelli I; Segni M; Mancini MA; Troiani S
    J Clin Endocrinol Metab; 1996 Mar; 81(3):948-51. PubMed ID: 8772556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.
    Palmert MR; Mansfield MJ; Crowley WF; Crigler JF; Crawford JD; Boepple PA
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4480-8. PubMed ID: 10599706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of gonadotropin-releasing hormone analogs treatment on final height in girls with central precocious puberty].
    Chen SK; Fan X; Tang Q
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 May; 11(5):374-6. PubMed ID: 19470261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
    Pasquino AM; Pucarelli I; Accardo F; Demiraj V; Segni M; Di Nardo R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone.
    Pasquino AM; Pucarelli I; Roggini M; Segni M
    J Clin Endocrinol Metab; 2000 Feb; 85(2):619-22. PubMed ID: 10690865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
    Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
    J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study.
    Magiakou MA; Manousaki D; Papadaki M; Hadjidakis D; Levidou G; Vakaki M; Papaefstathiou A; Lalioti N; Kanaka-Gantenbein C; Piaditis G; Chrousos GP; Dacou-Voutetakis C
    J Clin Endocrinol Metab; 2010 Jan; 95(1):109-17. PubMed ID: 19897682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs.
    Brito VN; Latronico AC; Cukier P; Teles MG; Silveira LF; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2662-9. PubMed ID: 18460564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum concentrations of type I and III procollagen propeptides in healthy children and girls with central precocious puberty during treatment with gonadotropin-releasing hormone analog and cyproterone acetate.
    Hertel NT; Stoltenberg M; Juul A; Main KM; Müller J; Nielsen CT; Lorenzen I; Skakkebaek NE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):924-7. PubMed ID: 8473407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty.
    Tung YC; Lee JS; Tsai WY; Hsiao PH
    J Formos Med Assoc; 2007 Oct; 106(10):826-31. PubMed ID: 17964961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty.
    Manasco PK; Pescovitz OH; Feuillan PP; Hench KD; Barnes KM; Jones J; Hill SC; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1988 Aug; 67(2):368-72. PubMed ID: 3292562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.